NCT00003995View on ClinicalTrials.gov

Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 1999

Primary Completion Date

March 31, 2006

Conditions
Colorectal Cancer
Interventions
BIOLOGICAL

trastuzumab

DRUG

irinotecan hydrochloride

Trial Locations (5)

10461

Albert Einstein Comprehensive Cancer Center, The Bronx

15213

University of Pittsburgh Cancer Institute, Pittsburgh

37203

Sarah Cannon-Minnie Pearl Cancer Center, Nashville

77030

University of Texas - MD Anderson Cancer Center, Houston

02906

Lifespan: The Miriam Hospital, Providence

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00003995 - Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2 | Biotech Hunter | Biotech Hunter